BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary ...

Testing for these mutations could be used to identify patients at a higher risk of dying from infection and inform disease management strategies. The study, published in the journal Leukemia and led ...

CLL is the result of various genetic mutations in the DNA of cells that produce blood. These DNA changes occur over the course of a lifetime, rather than like other genetic changes that are passed ...

The NOTCH1gene encodes a ligand-activated transcription factor and is affected by stabilizing mutations in 10% CLL at diagnosis, 20% chemorefractory CLL and 30% of cases of Richter syndrome.

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

Defects in the DNA damage sensors, particularly in the ataxia telengiectasia mutated (ATM)/TP53 pathways, confer resistance to standard chemotherapic agents used in CLL [4] that inflict DNA damage ...

BeiGene’s Test Before Treat campaign and partnership with the CLL Society aims to educate cancer patients about the ...

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...